8-K: Arcturus Therapeutics Reports Q1 2024 Results, Highlights Pipeline Progress and Kostaive Commercialization

Arcturus Therapeutics announced its first quarter 2024 financial results, along with updates on its pipeline progress, including the commercialization of Kostaive and key clinical trial milestones.

Summary

• Arcturus Therapeutics reported a net loss of $26.8 million for the first quarter of 2024, compared to a net income of $50.8 million in the same period last year.
• The company's revenue decreased to $38.0 million from $80.3 million year-over-year, primarily due to a reduction in revenue from the CSL agreement.
• Operating expenses increased to $68.4 million from $65.5 million year-over-year, with research and development expenses rising to $53.6 million.
• Arcturus is on track to deliver the initial 4 million commercial doses of Kostaive in Q3 2024.
• The European Marketing Authorization Application (MAA) approval decision for Kostaive is expected in Q3 2024.
• The company has engaged JP Morgan to monetize its investment in ARCALIS JV in Japan.
• Arcturus' cash runway is projected to extend at least three years into the first quarter of fiscal year 2027.
• The company achieved approximately $420.1 million in upfront payments and milestones from CSL as of March 31, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the significant decrease in revenue and shift to a net loss, although there are positive developments in the pipeline and commercialization of Kostaive. The engagement of JP Morgan to monetize the ARCALIS JV is a positive sign, but the overall financial results are concerning.

Positives

• Commercial manufacture of Kostaive is on track for delivery of initial 4 million doses in Q3 2024.
• Multiple Kostaive Phase 3 trials demonstrate the breadth and durability of the STARR vaccine platform.
• The company's bivalent COVID-19 vaccine candidate, ARCT-2301, met the primary endpoint in a Phase 3 clinical study in Japan.
• The cash runway is strong for at least three years into the first quarter of fiscal year 2027.
• Arcturus has achieved approximately $420.1 million in upfront payments and milestones from CSL as of March 31, 2024.
• ARCT-810 was generally well tolerated with no serious or severe adverse events in Phase 1 studies.

Negatives

• Arcturus reported a net loss of $26.8 million for the first quarter of 2024, compared to a net income of $50.8 million in the same period last year.
• The company's revenue decreased to $38.0 million from $80.3 million year-over-year.
• Operating expenses increased to $68.4 million from $65.5 million year-over-year.

Risks

• The company's future success depends on the continued advancement of its pipeline and partnered programs.
• Clinical trial results may not be predictive of future clinical results.
• The company's ability to achieve commercial milestones under the CSL collaboration is subject to various factors.
• The monetization of Arcturus' interests in ARCALIS JV in Japan is subject to market conditions and other factors.
• The company's cash position and runway are subject to change based on various factors, including cash burn and milestone payments.

Future Outlook

Arcturus expects to deliver the initial 4 million commercial doses of Kostaive in Q3 2024, receive a European Marketing Authorization Application approval decision for Kostaive in Q3 2024, and continue to advance its pipeline programs with clinical study updates expected on July 1, 2024. The company anticipates continued milestone payments from CSL and has a cash runway extending at least three years into the first quarter of fiscal year 2027.

Management Comments

• Joseph Payne, President & CEO of Arcturus, stated that the company continues to make encouraging progress in both its vaccine and therapeutics pipeline.
• Joseph Payne also mentioned that they are excited to begin the commercialization of Kostaive this year in collaboration with CSL and Meiji Seika Pharma.
• Andrew Sassine, Chief Financial Officer of Arcturus Therapeutics, announced that they have engaged JP Morgan to monetize their stake in ARCALIS, their JV manufacturing operation in Japan.
• Andrew Sassine also stated that they will begin to qualify for commercial milestones under their CSL collaboration upon commencement of Kostaive revenues in Japan this year.

Industry Context

This announcement reflects the ongoing development and commercialization efforts in the mRNA therapeutics and vaccine space. Arcturus is competing with other companies in the development of mRNA-based vaccines and therapeutics for infectious diseases and rare diseases. The collaboration with CSL Seqirus highlights the importance of partnerships in the industry to bring products to market.

Comparison to Industry Standards

• The decrease in revenue compared to the previous year is significant, and it is important to compare this to other biotech companies with similar collaboration agreements.
• The company's cash runway of at least three years is a positive sign, but it is important to compare this to the cash burn rates of other companies in the sector.
• The progress of the Kostaive vaccine is comparable to other mRNA vaccine development programs, such as those from Moderna and BioNTech, but with a focus on different markets and partnerships.
• The development of ARCT-810 and ARCT-032 for rare diseases is in line with the industry trend of targeting niche markets with high unmet medical needs, similar to companies like Alnylam and Sarepta.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the shift to a net loss.
• Employees may be impacted by the company's financial performance and future strategic decisions.
• Customers and partners may be interested in the progress of the company's pipeline and commercialization efforts.
• Suppliers and creditors may be impacted by the company's financial health and ability to meet its obligations.

Next Steps

• Arcturus will deliver the initial 4 million commercial doses of Kostaive in Q3 2024.
• The company expects a European Marketing Authorization Application approval decision for Kostaive in Q3 2024.
• Arcturus will provide interim data and updates on ARCT-810 and ARCT-032 on July 1, 2024.
• The company will continue to advance its pipeline programs and clinical trials.
• Arcturus will continue to work with JP Morgan to monetize its investment in ARCALIS JV in Japan.

Key Dates

Keywords

mRNA, vaccines, therapeutics, Kostaive, ARCT-2138, ARCT-810, ARCT-032, CSL, ARCALIS, COVID-19, influenza, clinical trials, revenue, milestones